{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ewing+Sarcoma&page=3",
    "query": {
      "condition": "Ewing Sarcoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 263,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ewing+Sarcoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ewing+Sarcoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T05:23:45.639Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00038142",
      "title": "Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ewing's Sarcoma"
      ],
      "interventions": [
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dexrazoxane",
          "type": "DRUG"
        },
        {
          "name": "ImmTher",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "3 Years to 60 Years"
      },
      "enrollment_count": 46,
      "start_date": "1997-11",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2020-01-29",
      "last_synced_at": "2026-10-20T05:23:45.639Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00038142"
    },
    {
      "nct_id": "NCT04995003",
      "title": "HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma",
        "HER-2 Protein Overexpression",
        "Osteosarcoma",
        "Rhabdomyosarcoma",
        "Ewing Sarcoma",
        "Synovial Sarcoma",
        "Soft Tissue Sarcoma",
        "Undifferentiated Sarcoma"
      ],
      "interventions": [
        {
          "name": "T cells or CAR T cells",
          "type": "GENETIC"
        },
        {
          "name": "Pembrolizumab Injectable Product",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab Injectable Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 25,
      "start_date": "2021-12-07",
      "completion_date": "2043-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-20T05:23:45.639Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04995003"
    },
    {
      "nct_id": "NCT03213652",
      "title": "Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Malignant Solid Neoplasm",
        "Recurrent Ependymoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Hepatoblastoma",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Glioma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Primary Central Nervous System Neoplasm",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Refractory Ependymoma",
        "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Hepatoblastoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Glioma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration and Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ensartinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radionuclide Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 13,
      "start_date": "2018-04-17",
      "completion_date": "2027-10-05",
      "has_results": true,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-20T05:23:45.639Z",
      "location_count": 122,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03213652"
    },
    {
      "nct_id": "NCT00036959",
      "title": "ABT-751 in Treating Young Patients With Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Childhood Germ Cell Tumor",
        "Extragonadal Germ Cell Tumor",
        "Kidney Cancer",
        "Liver Cancer",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Sarcoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ABT-751",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 90,
      "start_date": "2002-03",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-10-20T05:23:45.639Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00036959"
    },
    {
      "nct_id": "NCT03155620",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Ann Arbor Stage III Non-Hodgkin Lymphoma",
        "Ann Arbor Stage IV Non-Hodgkin Lymphoma",
        "Histiocytic Sarcoma",
        "Juvenile Xanthogranuloma",
        "Langerhans Cell Histiocytosis",
        "Malignant Glioma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Ependymoma",
        "Recurrent Ewing Sarcoma",
        "Recurrent Glioma",
        "Recurrent Hepatoblastoma",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Primary Central Nervous System Neoplasm",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Soft Tissue Sarcoma",
        "Refractory Ewing Sarcoma",
        "Refractory Glioma",
        "Refractory Hepatoblastoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Primary Central Nervous System Neoplasm",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Rhabdoid Tumor",
        "Stage III Osteosarcoma AJCC v7",
        "Stage III Soft Tissue Sarcoma AJCC v7",
        "Stage IV Osteosarcoma AJCC v7",
        "Stage IV Soft Tissue Sarcoma AJCC v7",
        "Stage IVA Osteosarcoma AJCC v7",
        "Stage IVB Osteosarcoma AJCC v7",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration and Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ensartinib",
          "type": "DRUG"
        },
        {
          "name": "Erdafitinib",
          "type": "DRUG"
        },
        {
          "name": "Ivosidenib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Larotrectinib Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mutation Carrier Screening",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radionuclide Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Samotolisib",
          "type": "DRUG"
        },
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        },
        {
          "name": "Selumetinib Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        },
        {
          "name": "Tipifarnib",
          "type": "DRUG"
        },
        {
          "name": "Ulixertinib",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 1377,
      "start_date": "2017-07-31",
      "completion_date": "2027-01-06",
      "has_results": true,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-20T05:23:45.639Z",
      "location_count": 168,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03155620"
    },
    {
      "nct_id": "NCT00093821",
      "title": "Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Chronic Myelogenous Leukemia",
        "Childhood Desmoplastic Small Round Cell Tumor",
        "Disseminated Neuroblastoma",
        "Metastatic Childhood Soft Tissue Sarcoma",
        "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Metastatic Osteosarcoma",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Neuroblastoma",
        "Recurrent Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "tanespimycin",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 70,
      "start_date": "2004-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-10-20T05:23:45.639Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00093821"
    },
    {
      "nct_id": "NCT01969942",
      "title": "A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ewing Sarcoma"
      ],
      "interventions": [
        {
          "name": "allogeneic stem cell transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabina",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-04",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-10-20T05:23:45.639Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01969942"
    },
    {
      "nct_id": "NCT03618381",
      "title": "EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pediatric Solid Tumor",
        "Germ Cell Tumor",
        "Retinoblastoma",
        "Hepatoblastoma",
        "Wilms Tumor",
        "Rhabdoid Tumor",
        "Carcinoma",
        "Osteosarcoma",
        "Ewing Sarcoma",
        "Rhabdomyosarcoma",
        "Synovial Sarcoma",
        "Clear Cell Sarcoma",
        "Malignant Peripheral Nerve Sheath Tumors",
        "Desmoplastic Small Round Cell Tumor",
        "Soft Tissue Sarcoma",
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "second generation 4-1BBζ EGFR806-EGFRt",
          "type": "BIOLOGICAL"
        },
        {
          "name": "second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 44,
      "start_date": "2019-06-18",
      "completion_date": "2040-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-20T05:23:45.639Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03618381"
    },
    {
      "nct_id": "NCT01614795",
      "title": "Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Alveolar Soft Part Sarcoma",
        "Childhood Angiosarcoma",
        "Childhood Epithelioid Sarcoma",
        "Childhood Fibrosarcoma",
        "Childhood Gliosarcoma",
        "Childhood Leiomyosarcoma",
        "Childhood Liposarcoma",
        "Childhood Malignant Peripheral Nerve Sheath Tumor",
        "Childhood Synovial Sarcoma",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Osteosarcoma",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 46,
      "start_date": "2012-06-18",
      "completion_date": "2014-04-01",
      "has_results": true,
      "last_update_posted_date": "2018-12-11",
      "last_synced_at": "2026-10-20T05:23:45.639Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01614795"
    },
    {
      "nct_id": "NCT00161187",
      "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 37,
      "start_date": "2001-05",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2015-11-06",
      "last_synced_at": "2026-10-20T05:23:45.639Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00161187"
    }
  ]
}